Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index; 17 of the 55 sources its claims cite were checked for support.
Abstract
STUDY QUESTION: Do all ectopic endometrial lesions (endometriosis and adenomyosis) universally have activated estrogen signaling? SUMMARY ANSWER: Estrogen signaling diminishes concordantly with increased fibrosis in ectopic endometrium, with deep endometriotic (DE) lesions exhibiting an estrogen biosynthesis capability and estrogen receptor β (ERβ) expression level comparable to that of control endometrium but having suppressed ERα. WHAT IS KNOWN ALREADY: Endometriosis and adenomyosis are both estrogen-dependent diseases driven by estrogen-mediated lesional development, progression, and symptom manifestation. Of note, ectopic endometrium is thought to have the ability to synthesize estradiol (E2) in situ from cholesterol due to upregulation of aromatase (CYP19A1), steroidogenic acute regulatory protein (StAR), 3β-hydroxysteroid dehydrogenase type 2 (HSD3β2), and HSD17β1. In addition to increased estrogen biosynthesis, ERβ and G-protein coupled ER (GPER) are also overexpressed in ectopic endometrium. In particular, the prevailing view holds that prostaglandin E2 plays a vital role in facilitating estrogen biosynthesis and the upregulation of ERβ, positioning itself in the central nexus in a feed-forward loop linking hyperestrogenism and inflammation in all ectopic endometria. STUDY DESIGN, SIZE, DURATION: After obtaining written informed consent, we collected lesional tissues from 19 patients with ovarian endometriosis (OE) and 20 patients each with adenomyosis (AD) and DE. As controls, normal endometrial tissue samples (CT) were procured from 20 cycling women free of endometriosis and adenomyosis, and age- and menstrual phase-matched with patients in the other groups. Additionally, primary ectopic or control endometrial stromal cells derived from eight subjects in each of the OE, AD, DE, and CT groups were cultured for experiments. PARTICIPANTS/MATERIALS, SETTING, METHODS: We performed immunohistochemistry and western blotting to assess the expression of proteins key to the estrogen biosynthesis (StAR, HSD3β2, aromatase, and HSD17β1) and estrogen receptors (ERα, ERβ, and GPER). Fibrosis was quantified via Masson trichrome staining. Real-time RT-PCR was performed to assess corresponding gene expression levels. The estrogen concentrations in cell cultures of primary stromal cells derived from different tissues were also measured by ELISA. MAIN RESULTS AND THE ROLE OF CHANCE: Among all ectopic endometrial tissue samples, the extent of lesional fibrosis was the highest in the DE lesions, followed by the AD and then the OE lesions. The protein and gene expression levels of StAR, HSD3β2, aromatase, and HSD17β1, the four proteins critically involved in estrogen biosynthesis, were significantly higher than in the CT group in OE and AD lesions, but were lowest in DE lesions, which were comparable to that of control endometrium. There was a significantly negative correlation between the expression of these proteins and the extent of lesional fibrosis. Consistently, while the concentration of estrogen in culture supernatants from OE cells was significantly higher than those in CT, it was significantly reduced in AD and DE lesions. In fact, the estrogen concentration in DE cell supernatants was comparable with that in the CT group. The expression of ERβ and GPER was significantly higher in OE and AD lesions than in the CT group and progressively declined with increasing lesional fibrosis; in the DE group, their expression was comparable to the CT group. A significant negative correlation was observed between their expression and the extent of lesional fibrosis. No significant difference in ERα expression was found among different types of ectopic endometrium, but all showed significantly and uniformly lower expression than that of the CT endometrium. LIMITATIONS, REASONS FOR CAUTION: While diminished estrogen signaling concordant with increased lesional fibrosis was demonstrated, no mechanistic data were provided. In addition, while in this study several genes/proteins known to be key to estrogen signaling were evaluated, some other genes/proteins that are also involved in estrogen signaling, such as other members of the HSD17B family, were not evaluated. WIDER IMPLICATIONS OF THE FINDINGS: Our findings challenge the prevailing notion of activated in situ estrogen signaling in ectopic endometrium of all kinds via the feed-forward loop. As such, there is a need to re-appraise our treatment strategies, especially for lesions that are highly fibrotic and thus well advanced. In addition, our findings can be capitalized to help choose the best treatment modality and to inspire novel therapeutics for endometriosis and adenomyosis. STUDY FUNDING/COMPETING INTEREST(S): This research was supported in part by grant 82071623 (S.-W.G.) from the National Natural Science Foundation of China and by grant 202440057 (J.N.) from the Clinical Research Project of Shanghai Municipal Health Commission. S.-W.G. is a member of the Scientific Advisory Board of Heranova, BioSciences and of FimmCyte A.G., and has provided consultancy advice to these companies, as well as to Shanghai Huilun Biotechnology, but these activities had no bearing on this work. The other authors have no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
Overview
CoChat Summary
TL;DR
Estrogen signaling in ectopic endometrium diminishes as lesional fibrosis increases, with ovarian endometriosis (OE) and adenomyosis (AD) showing activated estrogen biosynthesis and receptor expression, while deep endometriosis (DE) resembles control endometrium. The findings challenge the view that all ectopic endometrium has universally activated in situ estrogen signaling via the PGE2–estrogen feed-forward loop.
Key findings
- Lesional fibrosis was highest in DE, followed by AD and then OE; within ectopic endometrium, fibrosis correlated positively with dysmenorrhea severity (Spearman’s r = 0.42, P = 0.0008).
- StAR, HSD3β2, aromatase, and HSD17β1 were significantly higher in OE and AD than control endometrium (IHC all P ≤ 0.023; RT-PCR all P ≤ 0.023; western blot all P ≤ 0.007), but DE levels were comparable to controls (IHC all P ≥ 0.091; RT-PCR all P ≥ 0.083; western blot all P ≥ 0.065).
- 17β-estradiol concentrations were 2.69-fold higher in OE and 1.76-fold higher in AD versus controls (P = 0.00017 and P = 0.0011), while DE was comparable to controls (P = 0.33). ERβ and GPER were higher in OE and AD but comparable in DE; ERα was uniformly lower in all ectopic endometrium than controls (IHC all P ≤ 0.014; RT-PCR P ≤ 0.021; western blot P ≤ 0.010).
- Except for stromal ERα (r = 0.11, P = 0.39), immunostaining levels of the other proteins were negatively correlated with fibrosis extent (all r ≤ −0.39, P ≤ 0.0022); collagen I protein was negatively correlated with 17β-estradiol concentration (r = −0.69, P = 0.00019).
Methods
- Tissue samples from 19 patients with OE, 20 with AD, 20 with DE, and 20 controls matched by age and menstrual phase; primary stromal cells from 8 subjects per group were cultured. Controls were premenopausal women undergoing hysterectomy for high-grade squamous intraepithelial lesions of the cervix, free of other benign or malignant gynecological diseases, and no hormonal medication for at least 3 months.
- Immunohistochemistry, Masson trichrome staining, real-time RT-PCR, western blotting, and ELISA were used to assess estrogen biosynthesis enzymes (StAR, HSD3β2, aromatase, HSD17β1), estrogen receptors (ERα, ERβ, GPER), fibrosis, and 17β-estradiol concentrations.
- Statistical analysis used Wilcoxon’s rank test, Pearson’s or Spearman’s correlation, and multiple linear regression incorporating age, menstrual phase, parity, and co-occurrence of OE, AD, DE, and uterine fibroids; analyses were performed in R version 4.4.2.
Limitations
- Stated: no mechanistic data were provided linking fibrosis and diminished estrogen signaling; several other estrogen-signaling genes/proteins, such as other HSD17B family members, were not evaluated.
- Stated: only diffuse AD samples were used, which may limit generalizability; sample size for each ectopic endometrium subtype was moderate, though collectively reasonably large.
- Evident from the text: the design is cross-sectional and observational, so causality cannot be established; controls were women undergoing hysterectomy for HSIL rather than healthy community controls, which may affect comparability of control endometrium.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
14 Valid · 1 Not valid · 21 Not checked · 92 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For example, the first studies reporting the overexpression of StAR, HSD3β2, aromatase, HSD17β1, ERβ, and GPER all used OE or AD tissue samples (Brandenberger et al., 1999; Fujimoto et al., 1999; Attar et al., 2009; Mehasseb et al., 2011; Samartzis et al., 2012), due, likely, to less prevalent occurrence and thus the difficulty in getting DE samples.”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Discussion
What the sources say
- Not checked — no full text of the sourcecites Brandenberger et al., 1999 matched to “Oestrogen receptor (ER)-alpha and ER- isoforms in normal endometrial and endometriosis-derived stromal cells” (1999) source
- Not checked — no full text of the sourcecites Fujimoto et al., 1999 matched to “Expression of oestrogen receptor-alpha and -beta in ovarian endometriomata” (1999) source
- Disputedcites Attar et al., 2009 matched to “Prostaglandin E2 Via Steroidogenic Factor-1 Coordinately Regulates Transcription of Steroidogenic Genes Necessary for Estrogen Synthesis in Endometriosis” (2009) sourceExperimental — accuracy not yet measured
The ‘Expression of steroidogenic genes in eutopic and ectopic endometrium’ section reports elevated StAR and aromatase, with an apparent but less significant HSD3B2 difference, using extraovarian (peritoneal) endometriosis tissues—not OE or AD tissues. ‘Tissue acquisition and processing’ says ovarian endometrioma cyst walls were also collected, but those supplied cells for culture rather than the reported tissue-expression comparison. Our copy provides no basis for judging which studies were first. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Since the extent of lesional fibrosis is a proxy for lesional developmental stage (Guo et al., 2015; Liu et al., 2016; Shen et al., 2016; Zhang et al., 2016)”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Discussion
What the sources say
- Supportedcites Guo et al., 2015 matched to “Dating endometriotic ovarian cysts based on the content of cyst fluid and its potential clinical implications” (2015) source
The Introduction describes a mostly fibrotic endometriotic cyst as being at a terminal developmental stage. The Discussion reports that cysts presumed to be older had more fibrotic tissue than younger ones, supporting fibrosis as a proxy for developmental stage in the ovarian cysts studied. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites Liu et al., 2016 matched to “Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis” (2016) source
- Not matchedcites Shen et al., 2016
An author–year citation the paper’s reference list doesn’t settle. We don’t search these by name.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“aromatase inhibitors show no superior efficacy (Csirzo et al., 2024).”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Introduction
What the sources say
- Partly supportedcites Csirzo et al., 2024 matched to “Comparative analysis of medical interventions to alleviate endometriosis-related pain: a systematic review and network meta-analysis” (2024) sourceExperimental — accuracy not yet measured
The Discussion reports that, for endometriosis-related dyspareunia, adding an aromatase inhibitor to combined hormonal contraceptives showed no significant advantage over contraceptives alone. But the paper also ranks aromatase-inhibitor combinations highest for some six-month pain outcomes, and it does not evaluate adenomyosis or efficacy for treating the diseases beyond pain relief. The unqualified claim is therefore broader than the findings. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, a 2005 trial of raloxifene (an estrogen antagonist) was terminated early and unexpectedly due to accelerated pain recurrence and surgical reintervention in treated patients (Stratton et al., 2008).”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Introduction
What the sources say
- Partly supportedcites Stratton et al., 2008 matched to “Return of Chronic Pelvic Pain From Endometriosis After Raloxifene Treatment: A Randomized Controlled Trial” (2008) sourceExperimental — accuracy not yet measured
The Results report that the study was stopped early because raloxifene-treated women experienced pain recurrence and underwent second surgery significantly sooner than placebo-treated women. Materials and Methods dates the decision to stop the study to December 2004, not 2005. The Results also say raloxifene did not increase the likelihood of second surgery; it occurred earlier. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“adenomyosis (AD) and certain subtypes of endometriosis, such as deep endometriosis (DE), do not respond to hormonal treatment as well as ovarian endometrioma (OE) (Stratopoulou et al., 2021; Vannuccini et al., 2022)”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Introduction
What the sources say
- Partly supportedcites Stratopoulou et al., 2021 matched to “Conservative management of uterine adenomyosis: medical vs. surgical approach” (2021) sourceExperimental — accuracy not yet measured
Section 2.3 (Progestins; page not provided) reports that approximately one-third of patients with adenomyosis do not respond to progestins. The paper does not establish that adenomyosis or deep endometriosis responds less well to hormonal treatment than ovarian endometrioma; section 2.6 discusses deep endometriosis without making that comparison. (LLM, conf=0.86)
- Partly supportedcites Vannuccini et al., 2022 matched to “Hormonal treatments for endometriosis: The endocrine background” (2022) sourceExperimental — accuracy not yet measured
The Progestins section reports that dienogest reduced ovarian endometrioma size, while a study of deep infiltrating endometriosis found pain relief without a reduction in nodule volume. This supports a narrower difference in lesion-size response to dienogest, but the section does not establish that deep endometriosis responds less well to hormonal treatment overall or that adenomyosis does. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
59 more claims · 1 with their cited sources checked
Create a free account to see all 128 claims and to verify the 3 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 28
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| None | 20 (100%) | 6 (31.6%)*** | 4 (20.0%)*** | 3 (13.0%)*** |”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Differential extent of lesional fibrosis in different types of ectopic endometrium
Reported 13 · recomputed 15
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Validation by RT-PCR and western blotting
“Figure 5. Results of gene expression analysis. Relative fold change in gene expression of STAR, HSD3B2, CYP19A1, HSD17B1, ESR1, ESR2, and G-protein coupled ER (GPER) (A–G).”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Validation by RT-PCR and western blotting
“All data were expressed as fold change in protein expression relative to the CT group.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Estrogen concentrations in different types of ectopic endometrium
“as compared with the CT group (P = 0.00017, and P = 0.0011; Fig. 5H).”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Validation by RT-PCR and western blotting
“(H) Estradiol concentrations measured by ELISA in supernatant of cultured cells derived from different tissues.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Differential extent of lesional fibrosis in different types of ectopic endometrium
“| Mean±SD | 0.0 ± 4.3 |”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Differential extent of lesional fibrosis in different types of ectopic endometrium
“| [Min, Max] | [0, 0] |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Differential extent of lesional fibrosis in different types of ectopic endometrium
“[33.0, 9.0]”
§ Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium > Results > Differential extent of lesional fibrosis in different types of ectopic endometrium
“40.9 ± 5.0NS”
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Giudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
Nnoaham, K. E., Hummelshoj, L., Webster, P., d’Hooghe, T., de Cicco Nardone, F., de Cicco Nardone, C., Jenkinson, C., Kennedy, S. H., & Zondervan, K. T. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.090 · Cited by 1,584
Simoens, S., Dunselman, G., Dirksen, C., Hummelshoj, L., Bokor, A., Brandes, I., Brodszky, V., Canis, M., Colombo, G. L., DeLeire, T., et al. (2012) · Human Reproduction · doi:10.1093/humrep/des073 · Cited by 1,070 · cited 1×
“These symptoms contribute to a significant reduction in work productivity and quality of life, and an increased healthcare burden on patients globally (Nnoaham et al. , 2011; Simoens et al. , 2011, 2012).”
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Self-citationAromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 2×
“For example, the first report of aromatase upregulation used 17 lesion samples and 7 control endometrial samples (Noble et al. , 1996), while that on ER α used 9 and 11 samples, respectively (Brandenberger et al. , 1999).”
Zimmermann, A., Bernuit, D., Gerlinger, C., Schaefers, M., & Geppert, K. (2012) · BMC Women's Health · doi:10.1186/1472-6874-12-6 · Cited by 556 · cited 1×
“Endometriosis and adenomyosis are among the most prevalent gynecological disorders in women of reproductive age, second only to uterine fibroids (Zimmermann et al. , 2012).”
Bulun, S. E., Lin, Z., Imir, G., Amin, S., Demura, M., Yilmaz, B., Martin, R., Utsunomiya, H., Thung, S., Gurates, B., et al. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.3.6 · Cited by 531 · cited 3×
“…results also align with our previous report of diminished PGE 2 signaling in concordance with increasing fibrosis in ectopic endometrium (Yi et al. , 2025) since PGE 2 signaling plays a pivotal role in the feed-forward loop in estrogen biosynthesis in endo-metriotic lesions (Bulun et al. , 2005).”
Diagnosing adenomyosis: an integrated clinical and imaging approach
Chapron, C., Vannuccini, S., Santulli, P., Abrão, M. S., Carmona, F., Fraser, I. S., Gordts, S., Guo, S.-W., Just, P.-A., Noël, J.-C., et al. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz049 · Cited by 416
Self-citationPromoter Methylation Regulates Estrogen Receptor 2 in Human Endometrium and Endometriosis1
Xue, Q., Lin, Z., Cheng, Y.-H., Huang, C.-C., Marsh, E., Yin, P., Milad, M. P., Confino, E., Reierstad, S., Innes, J., et al. (2007) · Biology of Reproduction · doi:10.1095/biolreprod.107.061804 · Cited by 346
Naftalin, J., Hoo, W., Pateman, K., Mavrelos, D., Holland, T., & Jurkovic, D. (2012) · Human Reproduction · doi:10.1093/humrep/des332 · Cited by 336
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336 · cited 1×
“…adenomyosis (AD) and certain subtypes of endometriosis, such as deep endometriosis (DE), do not respond to hormonal treatment as well as ovarian endometrioma (OE) (Stratopoulou et al. , 2021; Vannuccini et al. , 2022), and aromatase inhibitors show no superior efficacy (Csirzo et al. , 2024).”
Hormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis
Brown, J., Crawford, T. J., Allen, C., Hopewell, S., & Prentice, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004753.pub4 · Cited by 308
Zeitoun, K., Takayama, K., Sasano, H., Suzuki, T., Moghrabi, N., Andersson, S., Johns, A., Meng, L., Putman, M., Carr, B., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.12.5301 · Cited by 308
Kitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305
Time to redefine endometriosis including its pro-fibrotic nature
Vigano, P., Candiani, M., Monno, A., Giacomini, E., Vercellini, P., & Somigliana, E. (2018) · Human Reproduction · doi:10.1093/humrep/dex354 · Cited by 235 · cited 1×
“Traditionally viewed as the elephant in the room, lesional fibrosis is now increasing recognized as an important feature of endometriosis (Guo, 2018; Vigano et al. , 2018) and adenomyosis (Guo, 2022).”
Xue, Q., Lin, Z., Yin, P., Milad, M. P., Cheng, Y.-H., Confino, E., Reierstad, S., & Bulun, S. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0494 · Cited by 219
Pinzauti, S., Lazzeri, L., Tosti, C., Centini, G., Orlandini, C., Luisi, S., Zupi, E., Exacoustos, C., & Petraglia, F. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14834 · Cited by 209
Attar, E., Tokunaga, H., Imir, G., Yilmaz, M. B., Redwine, D., Putman, M., Gurates, B., Attar, R., Yaegashi, N., Hales, D. B., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1180 · Cited by 207
Huhtinen, K., Desai, R., Ståhle, M., Salminen, A., Handelsman, D. J., Perheentupa, A., & Poutanen, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1154 · Cited by 195 · cited 3×
“In fact, the same study also reported a 6-fold higher E 2 concentration in OE lesions as compared with normal endometrium, but practically comparable E 2 concentration in DE lesions (Huhtinen et al. , 2012).”
Liu, X., Shen, M., Qi, Q., Zhang, H., & Guo, S.-W. (2016) · Human Reproduction · doi:10.1093/humrep/dew018 · Cited by 190 · cited 3×
“Second, the strength of estrogen signaling, in terms of estrogen production or ER activity, depends critically on the extent of lesional fibrosis, a proxy of the developmental stage of the lesions (Zhang et al. , 2016; Guo, 2018).”
Self-citationMedical treatment of endometriosis-related pain
Vercellini, P., Buggio, L., Frattaruolo, M. P., Borghi, A., Dridi, D., & Somigliana, E. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.015 · Cited by 188
Endometriosis—A disease because it is characterized by bleeding
Brosens, I. A. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70482-4 · Cited by 169
Mehasseb, M. K., Panchal, R., Taylor, A. H., Brown, L., Bell, S. C., & Habiba, M. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.02.051 · Cited by 165 · cited 3×
“…signaling as well as reduced ER α expression in OE and AD lesions are consistent with over-whelming data showing the same (Yamamoto et al. , 1993; Brandenberger et al. , 1999; Fujimoto et al. , 1999; Attar et al. , 2009; Mehasseb et al. , 2011; Heublein et al. , 2012; Samartzis et al. , 2012).”
Brandenberger, A. W. (1999) · Molecular Human Reproduction · doi:10.1093/molehr/5.7.651 · Cited by 165
Cyclooxygenase-2 in Endometriosis
Lai, Z.-Z., Yang, H.-L., Ha, S.-Y., Chang, K.-K., Mei, J., Zhou, W.-J., Qiu, X.-M., Wang, X.-Q., Zhu, R., Li, D.-J., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.35128 · Cited by 162
Tsai, S.-J., Wu, M.-H., Lin, C.-C., Sun, H. S., & Chen, H.-M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8082 · Cited by 155
Zhang, Q., Duan, J., Olson, M., Fazleabas, A., & Guo, S.-W. (2016) · Reproductive Sciences · doi:10.1177/1933719116641763 · Cited by 149
Self-citationEstrogen receptor β: the guardian of the endometrium
Hapangama, D. K., Kamal, A. M., & Bulmer, J. N. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu053 · Cited by 145
Adenomyosis: the pathophysiology of an oestrogen-dependent disease
Kitawaki, J. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.01.010 · Cited by 143
Trukhacheva, E., Lin, Z., Reierstad, S., Cheng, Y.-H., Milad, M., & Bulun, S. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1466 · Cited by 143 · cited 1×
“The ER α downregulation in endometriosis has been reported to be attributable to ER β overexpression that suppresses ESR1 expression since the ER β protein binds to the ESR1 gene promoter (Trukhacheva et al. , 2009).”
Loss of HDAC3 results in nonreceptive endometrium and female infertility
Kim, T. H., Yoo, J.-Y., Choi, K.-C., Shin, J.-H., Leach, R. E., Fazleabas, A. T., Young, S. L., Lessey, B. A., Yoon, H.-G., & Jeong, J.-W. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf7533 · Cited by 140
Stratton, P., Sinaii, N., Segars, J., Koziol, D., Wesley, R., Zimmer, C., Winkel, C., & Nieman, L. K. (2008) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000297307.35024.b5 · Cited by 140
Ding, D., Liu, X., Duan, J., & Guo, S.-W. (2015) · Human Reproduction · doi:10.1093/humrep/dev025 · Cited by 139
Self-citationProstaglandin E 2 : the master of endometriosis?
Wu, M.-H., Lu, C.-W., Chuang, P.-C., & Tsai, S.-J. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.009321 · Cited by 134
Šmuc, T., Pucelj, M. R., Šinkovec, J., Husen, B., Thole, H., & Rižner, T. L. (2007) · Gynecological Endocrinology · doi:10.1080/09513590601152219 · Cited by 124
Shen, M., Liu, X., Zhang, H., & Guo, S.-W. (2015) · Human Reproduction · doi:10.1093/humrep/dev314 · Cited by 124 · cited 1×
“Since the extent of lesional fibrosis is a proxy for lesional developmental stage (Guo et al. , 2015; Liu et al. , 2016; Shen et al. , 2016; Zhang et al. , 2016), its quantification provides a yardstick with which we can compare all ectopic endometrium over their entire spectrum.”
Self-citationExpression of oestrogen receptor-alpha and -beta in ovarian endometriomata
Fujimoto, J. (1999) · Molecular Human Reproduction · doi:10.1093/molehr/5.8.742 · Cited by 123 · cited 3×
“…signaling as well as reduced ER α expression in OE and AD lesions are consistent with over-whelming data showing the same (Yamamoto et al. , 1993; Brandenberger et al. , 1999; Fujimoto et al. , 1999; Attar et al. , 2009; Mehasseb et al. , 2011; Heublein et al. , 2012; Samartzis et al. , 2012).”
Guo, S.-W. (2018) · Human Reproduction · doi:10.1093/humrep/dey015 · Cited by 116
Self-citationDiagnosis, Evaluation, and Treatment of Adenomyosis
Kho, K. A., Chen, J., & Halvorson, L. M. (2021) · JAMA · doi:10.1001/jama.2020.26436 · Cited by 115
Evidence for estrogen synthesis in adenomyotic tissues
Yamamoto, T., Noguchi, T., Tamura, T., Kitawaki, J., & Okada, H. (1993) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(93)90654-2 · Cited by 111 · cited 1×
“…of activated estrogen signaling as well as reduced ER α expression in OE and AD lesions are consistent with over-whelming data showing the same (Yamamoto et al. , 1993; Brandenberger et al. , 1999; Fujimoto et al. , 1999; Attar et al. , 2009; Mehasseb et al. , 2011; Heublein et al. , 2012;…”
Liu, X., Zhang, Q., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719117718275 · Cited by 110 · cited 5×
“Aside from reduced vascularity and more epigenetic aberrations in lesions due to increased fibrosis (Liu et al. , 2018b), it is insensitive to ex-ternal deprivation of estrogen, which also explains as why the addition of aromatase inhibitors to other hormonal drugs or, alternatively, the use of…”
InfluentialSelf-citationDisturbed estrogen and progesterone action in ovarian endometriosis
Šmuc, T., Hevir, N., Ribič-Pucelj, M., Husen, B., Thole, H., & Rižner, T. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.07.020 · Cited by 101 · cited 1×
“…dehydrogenase type 2 (HSD3 β 2), which converts dehydroepian-drosterone to androstenedione, that can be further converted to estrone (E 1 ) by aromatase, and HSD17 β 1, which converts E 1 into E 2 , a more potent estrogen, are also aberrantly upregulated (Attar et al. , 2009; Smuc et al. , 2009).”
Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology
Guo, S. (2022) · Reproduction · doi:10.1530/rep-22-0224 · Cited by 101
Self-citationEndometriosis Cost Assessment (the EndoCost Study): A Cost-of-Illness Study Protocol
Simoens, S., Hummelshoj, L., Dunselman, G., Brandes, I., Dirksen, C., D’Hooghe, T., & EndoCost Consortium (2011) · Gynecologic and Obstetric Investigation · doi:10.1159/000316055 · Cited by 99
Nie, M., Xie, Q., Wu, Y., He, H., Zou, L., She, X., & Wu, X. (2018) · Journal of Immunology Research · doi:10.1155/2018/6285813 · Cited by 96
Guo, S.-W., Ding, D., Shen, M., & Liu, X. (2015) · Reproductive Sciences · doi:10.1177/1933719115570907 · Cited by 86 · cited 2×
“This is particularly relevant since the extent of fibrosis in ectopic endometrium is associated with the lesional developmental stage (Guo et al. , 2015; Zhang et al. , 2016) and severity of dysmenorrhea (Liu et al. , 2018a; Nie et al. , 2022), and is implicated to be responsible for heavy…”
Self-citationTransvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis
Liu, X., Ding, D., Ren, Y., & Guo, S. (2018) · Reproductive Sciences · doi:10.1177/1933719117750752 · Cited by 83
Self-citationLeonardo-Pinto, J. P., Benetti-Pinto, C. L., Cursino, K., & Yela, D. A. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.02.015 · Cited by 72 · cited 1×
“Also, this explains why dienogest treatment for an extended period could alleviate symptoms but has no cytoreductive effect on DE lesions (Leonardo-Pinto et al. , 2017).”
Chronic stress accelerates the development of endometriosis in mouse through adrenergic receptor β2
Long, Q., Liu, X., Qi, Q., & Guo, S.-W. (2016) · Human Reproduction · doi:10.1093/humrep/dew237 · Cited by 64
Self-citationIncreased Immunoreactivity to SLIT/ROBO1 in Ovarian Endometriomas
Shen, F., Liu, X., Geng, J.-G., & Guo, S. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090024 · Cited by 64
Self-citationConservative management of uterine adenomyosis: medical vs. surgical approach
Stratopoulou, C. A., Donnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214878 · Cited by 62 · cited 1×
“…adenomyosis (AD) and certain subtypes of endometriosis, such as deep endometriosis (DE), do not respond to hormonal treatment as well as ovarian endometrioma (OE) (Stratopoulou et al. , 2021; Vannuccini et al. , 2022), and aromatase inhibitors show no superior efficacy (Csirzo et al. , 2024).”
An overview of the current status of clinical trials on endometriosis: issues and concerns
Guo, S. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.08.050 · Cited by 55
Self-citationHow does the extent of fibrosis in adenomyosis lesions contribute to heavy menstrual bleeding?
Huang, Q., Liu, X., Critchley, H., Fu, Z., & Guo, S. (2022) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12442 · Cited by 52
Self-citationNie, J., Zhao, C., Laganà, A. S., Liu, X., & Guo, S. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.04.016 · Cited by 51
Self-citationKoninckx, P. R., Ussia, A., Wattiez, A., Adamyan, L., Martin, D. C., & Gordts, S. (2021) · Facts, Views and Vision in ObGyn · doi:10.52054/fvvo.13.3.028 · Cited by 50
Heublein, S., Lenhard, M., Vrekoussis, T., Schoepfer, J., Kühn, C., Friese, K., Makrigiannakis, A., Mayr, D. C., & Jeschke, U. (2012) · Reproductive Sciences · doi:10.1177/1933719112446085 · Cited by 50
Vannuccini, S., Meleca, C. I., Toscano, F., Mertino, P., Pampaloni, F., Fambrini, M., Bruni, V., & Petraglia, F. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.103768 · Cited by 50
Two unsuccessful clinical trials on endometriosis and a few lessons learned
Guo, S.-W., & Olive, D. L. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000098413 · Cited by 49 · cited 1×
“A phase II clinical trial launched in 1999, with great fanfare, on the use of fulvestrant (a potent pure anti-estrogen) for endometriosis, ended unceremoniously without a trace (Guo and Olive, 2007).”
Self-citationMEYER, J. L., ZIMBARDI, D., PODGAEC, S., AMORIM, R. L., ABRÃO, M. S., & RAINHO, C. A. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1637 · Cited by 47 · cited 2×
“Similarly, there are also conflicting data on ESR2 promoter hypo-methylation in OE lesions (Xue et al. , 2007a; Meyer et al. , 2014; Maekawa et al. , 2019).”
Park, S., Ham, J., Yang, C., Park, W., Park, H., An, G., Song, J., Hong, T., Park, S. J., Kim, H. S., et al. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12842 · Cited by 46
Liao, T.-L., Lee, Y.-C., Tzeng, C.-R., Wang, Y.-P., Chang, H.-Y., Lin, Y.-F., & Kao, S.-H. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.01.022 · Cited by 44
Aberrant DNA methylation suppresses expression of estrogen receptor 1 (ESR1) in ovarian endometrioma
Maekawa, R., Mihara, Y., Sato, S., Okada, M., Tamura, I., Shinagawa, M., Shirafuta, Y., Takagi, H., Taketani, T., Tamura, H., et al. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0489-1 · Cited by 44
Samartzis, N., Samartzis, E. P., Noske, A., Fedier, A., Dedes, K. J., Caduff, R., Fink, D., & Imesch, P. (2012) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-10-30 · Cited by 43 · cited 3×
“…signaling as well as reduced ER α expression in OE and AD lesions are consistent with over-whelming data showing the same (Yamamoto et al. , 1993; Brandenberger et al. , 1999; Fujimoto et al. , 1999; Attar et al. , 2009; Mehasseb et al. , 2011; Heublein et al. , 2012; Samartzis et al. , 2012).”
Vercellini, P., Buggio, L., Borghi, A., Monti, E., Gattei, U., & Frattaruolo, M. P. (2018) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.13328 · Cited by 41
Burla, L., Kalaitzopoulos, D. R., Metzler, J. M., Scheiner, D., & Imesch, P. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.05.040 · Cited by 40
Heilier, J.-F., Donnez, O., Van Kerckhove, V., Lison, D., & Donnez, J. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.10.041 · Cited by 37
Huang, Q., Liu, X., & Guo, S. (2022) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12423 · Cited by 30
Self-citationZhan, H., Peng, B., Ma, J., Lin, K., Xu, K., Lin, J., Yong, P. J., Leung, P. C. K., Bedaiwy, M. A., & Lin, J. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.05.005 · Cited by 29
Diagnosing deep endometriosis using transvaginal elastosonography
Ding, D., Chen, Y., Liu, X., Jiang, Z., Cai, X., & Guo, S.-W. (2020) · Reproductive Sciences · doi:10.1007/s43032-019-00108-2 · Cited by 28 · cited 1×
“In fact, in view of the close correlation between lesional fibrosis and lesional stiffness per elastoso-nography (Liu et al. , 2018a; Ding et al. , 2020), our finding that the estrogen signaling diminishes concordantly with increasing lesional fibrosis calls for a re-appraisal of current treatment…”
Self-citationLü, X., Wu, Y. R., Gao, X., Wang, Y., Wang, L., & Sun, X. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.03.055 · Cited by 28
Various types of adenomyosis and endometriosis: in search of optimal management
Guo, S. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.03.021 · Cited by 27
Self-citationTian, Y., Kong, B., Zhu, W., Su, S., & Kan, Y. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700513 · Cited by 25 · cited 1×
“StAR, HSD17 β 1, aromatase, HSD3 β 2, ER α , ER β , and GPER are reported to be expressed in OE lesions (Kitawaki et al. , 1997; Tian et al. , 2009; Sroyraya et al. , 2018).”
Huang, Q., Liu, X., & Guo, S. (2022) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12426 · Cited by 24
Self-citationHDAC3 regulates stability of estrogen receptor α mRNA
Oie, S., Matsuzaki, K., Yokoyama, W., Murayama, A., & Yanagisawa, J. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.007 · Cited by 21
Colette, S., & Donnez, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090328 · Cited by 20
Csirzó, Á., Kovács, D. P., Szabó, A., Szabó, B., Jankó, Á., Hegyi, P., Nyirády, P., Ács, N., & Valent, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226932 · Cited by 16
Mao, C., Liu, X., & Guo, S. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.103288 · Cited by 15
Self-citationExpression of 17 beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis
Carneiro, M. M., Morsch, D. M., Camargos, A. F., Spritzer, P. M., & Reis, F. M. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701200850 · Cited by 14
Clinicopathological correlations of peritoneal endometriosis and deep infiltrating endometriosis
Qiu, M.-Y., Wang, Y., Ren, R., Sun, Y.-R., Xiao, S.-Q., & Han, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2244877 · Cited by 12
Chiappini, F., Ceballos, L., Olivares, C., Bastón, J. I., Miret, N., Pontillo, C., Zárate, L., Singla, J. J., Farina, M., Meresman, G., et al. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.112867 · Cited by 11
Sroyraya, M., Songkoomkrong, S., Changklungmoa, N., Poljaroen, J., Weerakiet, S., Sophonsritsuk, A., Wongkularb, A., Lertvikool, S., Tingthanatikul, Y., & Sobhon, P. (2018) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2018.07.001 · Cited by 11
Yi, Y., Nie, J., Liu, X., & Guo, S. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01658-w · Cited by 7
Self-citationShen, M., Liu, X., Ding, D., & Guo, S.-W. (2025) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2025.104880 · Cited by 7
Self-citation
Cited by
Endometriosis and comorbidities: molecular mechanisms and clinical implications
Petraglia, F., Vannuccini, S., Donati, C., Jeljeli, M. M., Bourdon, M., & Chapron, C. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.09.002 · Cited by 27
Endometrial Stromal Cells from Endometriosis Patients Reflect Lesion-Type-Specific Heterogeneity
Gutierrez, D. R., Spalinger, M. R., Astourian, A., Evrova, O., Berclaz, L., Hartmann, M., Dedes, I., Imesch, P., Metzler, J. M., Witzel, I., et al. (2025) · Cells · doi:10.3390/cells14231891 · Cited by 6
Matsuzaki, S., & Canis, M. J. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.114788 · Cited by 4
Phenotypic heterogeneity in adenomyosis: internal and external subtypes
Liang, Y., Zhu, M., Sun, F., Liu, X., Liu, J., & Zhang, J. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08166-5 · Cited by 3
Self-citationUrbanek, O., Osial, M. E., Zaszczyńska, A., Lustyk, Ł., & Pavone, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119734 · Cited by 1
Metadata
- Authors
- Nie, J., Yi, Y., Liu, X., & Guo, S.-W.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Corresponding author
- Guo, Sun-Wei
- Venue
- Human Reproduction Open
- Publisher
- Oxford University Press (OUP)
- Published
- 2025
- Volume
- 2025
- Issue
- 3
- Pages
- hoaf028-hoaf028
- ISSN
- 2399-3529 (ISSN-L)
- PMC
- PMC12165729
- OpenAlex
- W4410398443
- Cited by
- 11
- References
- 86
- Citations by year
- 2026: 7 · 2025: 4
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Human Reproduction Open (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (202440057)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- endometriosis, adenomyosis, deep infiltrating endometriosis, estrogen signaling, fibrosis, estrogen synthesis, estrogen receptor beta, estrogen receptor alpha, G protein-coupled estrogen receptor, aromatase, steroidogenic acute regulatory protein, endometrial stromal cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.